Tags

Type your tag names separated by a space and hit enter

Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease.
Parkinsonism Relat Disord. 2015 Aug; 21(8):911-6.PR

Abstract

INTRODUCTION

Mitochondrial complex I deficiencies have been found in post-mortem brains of patients with Parkinson's disease (PD). Coenzyme Q10 (CoQ10) is the electron acceptor found in complexes I and II, and is a potent antioxidant. A recent trial of the oxidized form of CoQ10 for PD failed to show benefits; however, the reduced form of CoQ10 (ubiquinol-10) has shown better neuroprotective effects in animal models.

METHODS

Randomized, double-blind, placebo-controlled, parallel-group pilot trials were conducted to assess the efficacy of ubiquinol-10 in Japanese patients with PD. Participants were divided into two groups: PD experiencing wearing off (Group A), and early PD, without levodopa (with or without a dopamine agonist) (Group B). Participants took 300 mg of ubiquinol-10 or placebo per day for 48 weeks (Group A) or 96 weeks (Group B).

RESULTS

In Group A, total Unified Parkinson's Disease Rating Scale (UPDRS) scores decreased in the ubiquinol-10 group (n = 14; mean ± SD [-4.2 ± 8.2]), indicating improvement in symptoms. There was a statistically significant difference (p < 0.05) compared with the placebo group (n = 12; 2.9 ± 8.9). In Group B, UPDRS increased in the ubiquinol-10 group (n = 14; 3.9 ± 8.0), as well as in the placebo group (n = 8; 5.1 ± 10.3).

CONCLUSIONS

This is the first report showing that ubiquinol-10 may significantly improve PD with wearing off, as judged by total UPDRS scores, and that ubiquinol-10 is safe and well tolerated.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Yoritaka A
Department of Neurology, Juntendo University School of Medicine, Japan; Department of Neurology, Juntendo University Koshigaya Hospital, Japan.
Kawajiri S
Department of Neurology, Juntendo University School of Medicine, Japan.
Yamamoto Y
School of Bioscience and Biotechnology, Tokyo University of Technology, Japan.
Nakahara T
Department of Neurology, Juntendo University School of Medicine, Japan.
Ando M
Department of Neurology, Juntendo University School of Medicine, Japan.
Hashimoto K
School of Bioscience and Biotechnology, Tokyo University of Technology, Japan.
Nagase M
School of Bioscience and Biotechnology, Tokyo University of Technology, Japan.
Saito Y
Department of Neurology, Higashi Nagoya National Hospital, Japan.
Hattori N
Department of Neurology, Juntendo University School of Medicine, Japan. Electronic address: nhattori@juntendo.ac.jp.

MeSH

AgedAntioxidantsDouble-Blind MethodFemaleHumansMaleMiddle AgedNeuroprotective AgentsParkinson DiseasePilot ProjectsTreatment OutcomeUbiquinone

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

26054881

Citation

Yoritaka, Asako, et al. "Randomized, Double-blind, Placebo-controlled Pilot Trial of Reduced Coenzyme Q10 for Parkinson's Disease." Parkinsonism & Related Disorders, vol. 21, no. 8, 2015, pp. 911-6.
Yoritaka A, Kawajiri S, Yamamoto Y, et al. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease. Parkinsonism Relat Disord. 2015;21(8):911-6.
Yoritaka, A., Kawajiri, S., Yamamoto, Y., Nakahara, T., Ando, M., Hashimoto, K., Nagase, M., Saito, Y., & Hattori, N. (2015). Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease. Parkinsonism & Related Disorders, 21(8), 911-6. https://doi.org/10.1016/j.parkreldis.2015.05.022
Yoritaka A, et al. Randomized, Double-blind, Placebo-controlled Pilot Trial of Reduced Coenzyme Q10 for Parkinson's Disease. Parkinsonism Relat Disord. 2015;21(8):911-6. PubMed PMID: 26054881.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease. AU - Yoritaka,Asako, AU - Kawajiri,Sumihiro, AU - Yamamoto,Yorihiro, AU - Nakahara,Toshiki, AU - Ando,Maya, AU - Hashimoto,Kazuhiko, AU - Nagase,Midori, AU - Saito,Yufuko, AU - Hattori,Nobutaka, Y1 - 2015/05/29/ PY - 2015/01/04/received PY - 2015/05/25/revised PY - 2015/05/27/accepted PY - 2015/6/10/entrez PY - 2015/6/10/pubmed PY - 2016/5/7/medline KW - Complex I KW - Oxidative stress KW - Parkinson's disease KW - Randomized controlled trial KW - Reduced form of coenzyme Q10 SP - 911 EP - 6 JF - Parkinsonism & related disorders JO - Parkinsonism Relat Disord VL - 21 IS - 8 N2 - INTRODUCTION: Mitochondrial complex I deficiencies have been found in post-mortem brains of patients with Parkinson's disease (PD). Coenzyme Q10 (CoQ10) is the electron acceptor found in complexes I and II, and is a potent antioxidant. A recent trial of the oxidized form of CoQ10 for PD failed to show benefits; however, the reduced form of CoQ10 (ubiquinol-10) has shown better neuroprotective effects in animal models. METHODS: Randomized, double-blind, placebo-controlled, parallel-group pilot trials were conducted to assess the efficacy of ubiquinol-10 in Japanese patients with PD. Participants were divided into two groups: PD experiencing wearing off (Group A), and early PD, without levodopa (with or without a dopamine agonist) (Group B). Participants took 300 mg of ubiquinol-10 or placebo per day for 48 weeks (Group A) or 96 weeks (Group B). RESULTS: In Group A, total Unified Parkinson's Disease Rating Scale (UPDRS) scores decreased in the ubiquinol-10 group (n = 14; mean ± SD [-4.2 ± 8.2]), indicating improvement in symptoms. There was a statistically significant difference (p < 0.05) compared with the placebo group (n = 12; 2.9 ± 8.9). In Group B, UPDRS increased in the ubiquinol-10 group (n = 14; 3.9 ± 8.0), as well as in the placebo group (n = 8; 5.1 ± 10.3). CONCLUSIONS: This is the first report showing that ubiquinol-10 may significantly improve PD with wearing off, as judged by total UPDRS scores, and that ubiquinol-10 is safe and well tolerated. SN - 1873-5126 UR - https://www.unboundmedicine.com/medline/citation/26054881/full_citation DB - PRIME DP - Unbound Medicine ER -